You can buy or sell AQST and other stocks, options, ETFs, and crypto commission-free!
Aquestive Therapeutics, Inc. Common Stock, also called Aquestive Therapeutics, is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. Read More The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
Warren, New Jersey
52 Week High
52 Week Low
Simply Wall StMar 21
Have Insiders Been Buying Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares This Year?
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So we’ll take a look at whether insiders have been buying or selling shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST). What Is Insider Selling? It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, su...
Seeking AlphaMar 15
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2018 Results - Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2018 Earnings Conference Call March 14, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Dan Barber - Chief Strategy and Development Officer John Maxwell - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Randall Stanicky - RBC Capital Markets Liana Moussatos - Wedbush Securities Dougl...
PR NewswireMar 14
Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
WARREN, N.J., March 14, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on recent developments in its business. "Aquestive made significant progress in 2018 by launching our first proprietary product and continuing our transformation into a com...
-$0.51 per share
-$0.56 per share